The prevalence of obesity increases and is associated with increases in co-morbidities e.g. type 2 diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, heart disease, stroke, asthma, several forms of cancer, depression, and may result in reduction of expected remaining lifespan. We have reviewed the adverse effects on the cardiovascular system of anti-obesity drugs now retracted from the market as well as the cardiovascular profile of current drugs and potential pathways which are considered for treatment of obesity. Fenfluramine, and sibutramine were withdrawn due to increased cardiovascular risk, while an inverse agonist at cannabinoid type 1 (CB1) receptors, rimonobant was withdrawn due to serious psychiatric problems. At present there are only few treatments available including orlistat and, phentermine alone or in combination with topiramate and lorcaserin, although cardiovascular side effects need to be clarified regarding phentermine and lorcaserin. Drugs approved for type 2 diabetes including glucagon like peptide (GLP-1) analogues and metformin also cause moderate weight losses and have a favourable cardiovascular profile, while the anti-obesity potential of nebivolol remains unexplored. Pathways with anti-obesity potential include sirtuin activation, blockade of transient receptor potential (TRPV1) channels, acetyl-CoA carboxylase 1 and 2 inhibitors, uncoupling protein activators, bile acids, crotonins, CB1 antagonists, but the cardiovascular profile remains to be investigated. For type 2 diabetes, new drug classes with possible advantageous cardiovascular profiles, e.g. GLP-1 analogues and sodium-glucose co-transport type 2 inhibitors, are associated with weight loss and are currently being evaluated as anti-obesity drugs.
Keywords: Antiobesity drugs, brown adipose tissue, cardiovascular effects, incretins, TRPV1, SLGT2.
Respiratory Syncytial Virus and Asthma in Twin Children: Lessons from the Population-Based Danish Registries
Current Respiratory Medicine Reviews Antimicrobial Activity of Oleiyl Glucoside Isolated from the Traditional Medicinal Plant, Capparis decidua
The Natural Products Journal Macrophage Migration Inhibitory Factor: A Therapeutic Target Across Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Adenosine Receptors As Promising Therapeutic Targets for Drug Development in Chronic Airway Inflammation
Current Drug Targets Chemogenomics with Peptide Secondary Structure Mimetics
Combinatorial Chemistry & High Throughput Screening The IL-17 Family of Cytokines - Applications in Respiratory Medicine and Allergology
Recent Patents on Inflammation & Allergy Drug Discovery LC-MS/MS Identification and Structural Characterization of Main Biodegradation Products of Nitroproston - A Novel Prostaglandin-based Pharmaceutical Compound
Drug Metabolism Letters Chronopharmaceutical Delivery of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adipose Tissue in the Regulation of Inflammation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) Monoclonal Antibodies in Allergy; Current Applications and Promising Trials
Recent Patents on Inflammation & Allergy Drug Discovery Action Mechanism of Antihistamines and the New Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Induced Sputum in Asthma: From Bench to Bedside
Current Medicinal Chemistry Eicosanoids in Asthma, Allergic Inflammation, and Host Defense
Current Molecular Medicine A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery Ethnopharmacological and Phytopharmaceutical Evaluation of Prosopis cineraria: An Overview and Future Prospects
Current Drug Metabolism Severe Asthma: Why do Some Children Not Respond to Treatment?
Current Pediatric Reviews The Guinea Pig as an Animal Model for Asthma
Current Drug Targets An Overview of Different Analytical Techniques for Leukotriene Antagonists in Different Matrices
Current Pharmaceutical Analysis The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Measuring Control: How can Response to Asthma Treatment be Measured?
Current Pediatric Reviews